Aligning with other major biopharmaceutical companies to develop and commercialize Advaxis’s proprietary cancer immunotherapies.
Bristol-Myers Squibb Company
Advaxis and Bristol-Myers Squibb announced a clinical development collaboration to evaluate Advaxis’ axalimogene filolisbac and Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), as a potential combination treatment for women with persistent, recurrent or metastatic (squamous or non-squamous cell) carcinoma of the cervix. This combination immunotherapy regimen may offer a potential treatment option to patients with metastatic cervical cancer because they have complementary mechanisms of action, and both have independently shown potential for efficacy.
Merck & Co., Inc.
Advaxis entered into a clinical trial collaboration agreement with Merck to evaluate the combination of Advaxis’ ADXS-PSA with Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). The ongoing clinical trial evaluates the safety and efficacy of ADXS-PSA as monotherapy and in combination with KEYTRUDA® in a Phase 1/2 study of patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).
AstraZeneca / MedImmune
Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in combination with Advaxis’ axalimogene filolisbac as a treatment for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.